Xanomeline-Trospium: A Muscarinic Alternative to Dopamine Blockade
This narrative review consolidates the pharmacology, pharmacokinetics, and EMERGENT trial data behind the first non-dopaminergic antipsychotic, giving psychopharmacology pharmacists a mechanistic and practical framework for counseling and monitoring.
Cobenfy offers a novel way to treat schizophrenia with fewer side effects.
Cobenfy, combining xanomeline and trospium, offers a novel schizophrenia treatment minimizing common antipsychotic side effects. Cobenfy reduced PANSS scores significantly with a least squares mean difference of -9.6 and -8.4 in two trials. Major side effects include nausea and constipation. This new mechanism provides a valuable alternative for schizophrenia patients, especially those intolerant to dopamine antagonists. Long-term safety data are yet needed. Cobenfy effectively treats schizophrenia with fewer metabolic and extrapyramidal side effects than traditional antipsychotics.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Avila S, Chen IL
Citation:Avila S, Chen IL Xanomeline and Trospium Chloride: Mechanism of Action, Clinical, and Translational Science. Clinical and translational science. 2026;19(9):e70725. doi:10.1111/cts.70725